新型HSD17B13抑制剂用于治疗肝脏疾病
1Smith, Gambrell & Russell LLP, 1105 W. Peachtree Street NE, Suite 1000, Atlanta, Georgia 30309, United States.
ACS medicinal chemistry letters
|June 19, 2024
概括
针对HSD17B13 (氧类固醇17-β脱酶13) 的新型抑制剂为肝脏疾病提供了新的治疗策略. 这项研究介绍了创新的化合物及其制备方法,用于治疗肝脏疾病.
科学领域:
- 生物化学 生物化学
- 药用化学 医学化学
- 肝病学 肝病学是一种肝病学.
背景情况:
- 氧类固醇17-β脱酶13 (HSD17B13) 酶在肝细胞内的脂质代谢中起着至关重要的作用.
- HSD17B13的失调与各种慢性肝病的发病有关,包括非酒精性脂肪性肝病 (NAFLD) 和酒精性肝炎.
- 目前肝脏疾病的治疗选择有限,这凸显了需要新的药理干预措施的需要.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
646
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
646
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
146
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
146


